Fig. 2
From: An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells
Targeting of NFATc2 in melanoma cells downregulates EMT-related markers and AXL. a Expression by western blotting of NFATc2, ZEB1, N-cadherin, α-catulin, SNAIL, and E-cadherin in three melanoma cell lines (Me71, Me79, Me98) at 72 h after transfection with two different NFATc2-specific Stealth siRNA (NFATc2 siRNA-1 and siRNA-2) or with control siRNA (ctrl siRNA). b, c Expression of NFATc2, ZEB1, N-cadherin, α-catulin, SNAIL, and E-cadherin in b NFATc2 shRNA stable transfectants (NFATc2 shRNA_86a and NFATc2 shRNA_87a) or in control cells (ctrl shRNA), or c in melanoma cell lines Me71, Me79, and Me98 treated or not for 144 h with the NFATc2 inhibitor AM404 (at 20 μM). d Expression of NFATc2 and AXL in melanoma cell lines Me51 (top panels) and Me67 (bottom panels) after NFATc2 targeting by siRNA as in a, or by AM404 as in c
